<DOC>
	<DOCNO>NCT00266669</DOCNO>
	<brief_summary>The purpose study investigate efficacy safety topical gel formulation nitroglycerin , comparison match placebo , patient moderate severe primary Raynaud 's phenomenon patient Raynaud 's phenomenon secondary autoimmune disease , scleroderma .</brief_summary>
	<brief_title>Phase III Study Topical Gel Treatment Prevention Raynaud 's Phenomenon</brief_title>
	<detailed_description />
	<mesh_term>Raynaud Disease</mesh_term>
	<mesh_term>Nitroglycerin</mesh_term>
	<criteria>Clinical diagnosis Raynaud 's phenomenon 2 Raynaud 's event typical winter day Agree discontinue current treatment Raynaud 's Negative pregnancy test agree use effective contraception study Current use nitrate medication medication know interact nitroglycerin Patients currently use medication , like calcium channel blocker , might interfere study medication Patients know allergy nitroglycerin common topical ingredient Patients history migraine headache Patients history unstable medical problem Patients cognitive language difficulty would impair completion assessment instrument Patients lab screen value 20 % outside normal range Patients nonepithelialized skin lesion , area gel apply , time screen Pregnant nursing woman Women childbearing potential unwilling comply contraceptive requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>Raynaud 's Phenomenon</keyword>
	<keyword>Raynaud 's Disease</keyword>
	<keyword>Scleroderma</keyword>
	<keyword>Raynaud 's Disease Secondary Scleroderma</keyword>
	<keyword>Raynaud 's Disease Secondary Other Autoimmune Disease</keyword>
</DOC>